Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 9, 2006, Pages 2919-2925

  Bakker Woudenberg, Irma A J M ^a   Ten Kate, Marian T ^a   Goessens, Wil H F ^a   Mouton, Johan W ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFTAZIDIME;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CORRELATION ANALYSIS; DRUG EFFICACY; ENTEROBACTER INFECTION; EXPERIMENTAL INFECTION; KLEBSIELLA PNEUMONIAE; LUNG INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LUNG DISEASES; MALE; RATS;

EID: 33748696830     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00859-05     Document Type: Article

References (37)

1. Ambrose, P. G., D. M. Grasela, T. H. Grasela, J. Passarell, H. B. Mayer, and P. F. Pierce. 2001. Pharmacodynamics of fluoroquinolones against Streptococcus pneumonias in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793-2797.
2. Ambrose, P. G., J. B. Anon, J. S. Owen, S. van Wart, M. E. McPhee, S. M. Bhavnani, M. Piedmonte, and R. N. Jones. 2004. Use of pharmacodynamic endpoints in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. Clin. Infect. Dis. 38:1513-1520.
3. Andes, D., and W. A. Craig. 2002. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 2002. 19:261-268.
4. Bakker-Woudenberg, I. A. J. M., J. C. van den Berg, and M. F. Michel. 1982. Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally induced Klebsietta pneumoniae pneumonia in rats. Antimicrob. Agents Chemother. 22:1042-1050.
5. Bakker-Woudenberg, I. A. J. M., J. C. van den Berg, P. Fontijne, and M. F. Michel. 1984. Efficacy of continuous versus intermittent administration of penicillin G in Streptococcus pneumoniae pneumonia in normal and immunodeficient rats. Eur. J. Clin. Microbiol. 3:131-135.
6. Bakker-Woudenberg, I. A. J. M., J. C. van den Berg, T. B. Vree, A. M. Baars, and M. F. Michel. 1985. Relevance of serum protein binding of cefoxitin and cefazolin to their activities against Klebsiella pneumoniae pneumonia in rats. Antimicrob. Agents Chemother. 28:654-659.
7. Bennett, J. V., J. L. Brodie, E. J. Benner, and W. M. M. Kirby. 1966. Simplified, accurate method for antibiotic assay for clinical specimens. Appl. Microbiol. 14:170-177.
8. Clinical and Laboratory Standards Institute. 2005. Methods for dilution antimicrobial susceptibility testing for bacteria that grow aerobically; approved standard, sixth edition, and performance standards for antimicrobial susceptibility testing; fifteenth international supplement. CLSI document M100-S15. Clinical and Laboratory Standards Institute, Wayne, Pa.
9. 8a.Council of the European Community. 1986. Guidelines on the protection of experimental animals. Council of the European Community, Brussels, Belgium.
10. Craig, W. A. 1993. Post-antibiotic effects in experimental infection models: relationship to in vitro phenomena and to treatment of infections in man. J. Antimicrob. Chemother. 31(Suppl. D):149-158.
11. Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96.
12. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing in mice and men. Clin. Infect. Dis. 26:1-12.
13. Craig, W. A. 1998. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J. 77(6 Suppl.):7-11.
14. Craig, W. A. 2001. Does the dose matter? Clin. Infect. Dis. 33(Suppl. 3):S233-S237.
15. Craig, W. A. 2002. Pharmacodynamics of antimicrobials: general concepts and applications, p. 1-22. In C. H. Nightingale, T. Murakawa, and P. G. Ambrose (ed.), Antimicrobial pharmacodynamics in theory and clinical practice. Marcel Dekker, Inc., New York, N.Y.
16. Craig, W. A. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. N. Am. 17:479-501.
17. Drusano, G. L., S. L. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, and W. A. Craig. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
18. Drusano, G. L., S. L. Preston, C. Fowler, M. Corrado, B. Weisinger, and J. Kahn. 2004. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J. Infect. Dis. 189:1590-1597.
19. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
20. Forrest, A., S. Chodosh, M. A. Amantea, D. A. Collins, and J. J. Schentag. 1997. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 40(Suppl. A):45-57.
21. Hyatt, J. M., P. S. McKinnon, G. S. Zimmer, and J. J. Schentag. 1995. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin. Pharmacokinet. 28:143-160.
22. Leggett, J. E., B. Fantin, S. Ebert, K. Totsuka, B. Vogelman, W. Calame, H. Mattie, and W. A. Craig. 1989. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159:281-292.
23. Leggett, J. E., S. Ebert, B. Fantin, and W. A. Craig. 1991. Comparative dose-effect elations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand. J. Infect. Dis. Suppl. 74:179-184.
24. Mehrotra, R., R. De Gaudio, and M. Palazzo. 2004. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med. 30:2145-2156.
25. Mouton, J. W., M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55:601-607.
26. Mouton, J. W., N. Jacobs, H. Tiddens, and A. M. Horrevorts. 2005. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn. Microbiol. Infect. Dis. 52:123-127.
27. Mouton, J. W., and A. A. Vinks. 2005. Pharmacokinetic/pharmacodynamic modeling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin. Pharmacokinet. 44:201-210.
28. Mouton, J. W., N. C. Punt, and A. A. Vinks. 2005. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin. Ther. 27:762-772.
29. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. 1998. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125-129.
30. Roosendaal, R., I. A. J. M. Bakker-Woudenberg, J. C. van den Berg, and M. F. Michel. 1985. Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J. Infect. Dis. 152:373-378.
31. Roosendaal, R., J. C. van den Berg, M. van Raffe, and M. F. Michel. 1986. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob. Agents Chemother. 30:403-408.
32. Roosendaal, R., I. A. Bakker-Woudenberg, M. van den Berghe-van Raffe, J. C. Vink-van den Berg, and M. F. Michel. 1987. Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro. Pharm. Weekbl. Sci. 9(Suppl.):S33-S40.
33. Satta, G., G. Cornaglia, A. Mazzariol, G. Golini, S. Valisena, and R. Fontana. 1995. Target for bacteriostatic and bactericidal activities of beta-lactam antibiotics against Escherichia coli resides in different penicillin-binding proteins. Antimicrob. Agents Chemother. 39:812-818.
34. Turnidge, J. D. 1998. The pharmacodynamics of β-lactams. Clin. Infect. Dis. 27:10-22.
35. Vogelman, B., and W. A. Craig. 1986. Kinetics of antimicrobial activity. J. Pediatr. 108:835-840.
36. Vogelman, B., S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.
37. Wise, R. 2003. Maximizing efficacy and reducing the emergence of resistance. J. Antimicrob. Chemother. 51(Suppl. 1):37-42.